-+ 0.00%
-+ 0.00%
-+ 0.00%
Rohto Pharmaceutical Publishes 2026 Annual Report
Share
Listen to the news
Rohto Pharmaceutical Publishes 2026 Annual Report
  • Rohto Pharmaceutical published its 2026 integrated annual report, reporting record sales and operating profit for fiscal 2025.
  • Growth in Southeast Asia and contributions from Eu Yan Sang and MoNo supported overseas expansion.
  • The group expects to reach its fiscal 2027 sales target in fiscal 2026, one year ahead of schedule.
  • Medical operations remain a growth investment priority, with partnerships advancing regenerative medicine commercialization and contract manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending